• Nenhum resultado encontrado

Rev. Bras. Hematol. Hemoter. vol.31 suppl.2

N/A
N/A
Protected

Academic year: 2018

Share "Rev. Bras. Hematol. Hemoter. vol.31 suppl.2"

Copied!
6
0
0

Texto

Loading

Referências

Documentos relacionados

The 5-year OS after high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients who relapsed and in patients with primary resistance were 60% and

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the

High-dose Mel (1) followed by autologous stem cell transplantation (ASCT) has extensively been used in patients with multiple myeloma (MM), other lymphoid malignancies, such

Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/ refractory Hodgkin's lymphoma: results of the prospective multicenter

Comment on: Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation..

chemotherapy program without TBI using melphalan, cyclophosphamide and etoposide followed by consolidation-rescue with autologous hematopoietic progenitor stem cell

Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors. Biol Blood

Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.. Biol Blood